Suppr超能文献

N-糖组分析检测到 SLC39A8 缺陷中常规方法错过的糖基化异常。

N-glycome analysis detects dysglycosylation missed by conventional methods in SLC39A8 deficiency.

机构信息

Department of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden.

Department of General Pediatrics, University of Münster, Münster, Germany.

出版信息

J Inherit Metab Dis. 2020 Nov;43(6):1370-1381. doi: 10.1002/jimd.12306. Epub 2020 Sep 14.

Abstract

Congenital disorders of glycosylation (CDG) are a growing group of inborn metabolic disorders with multiorgan presentation. SLC39A8-CDG is a severe subtype caused by biallelic mutations in the manganese transporter SLC39A8, reducing levels of this essential cofactor for many enzymes including glycosyltransferases. The current diagnostic standard for disorders of N-glycosylation is the analysis of serum transferrin. Exome and Sanger sequencing were performed in two patients with severe neurodevelopmental phenotypes suggestive of CDG. Transferrin glycosylation was analyzed by high-performance liquid chromatography (HPLC) and isoelectric focusing in addition to comprehensive N-glycome analysis using matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry (MS). Atomic absorption spectroscopy was used to quantify whole blood manganese levels. Both patients presented with a severe, multisystem disorder, and a complex neurological phenotype. Magnetic resonance imaging (MRI) revealed a Leigh-like syndrome with bilateral T2 hyperintensities of the basal ganglia. In patient 1, exome sequencing identified the previously undescribed homozygous variant c.608T>C [p.F203S] in SLC39A8. Patient 2 was found to be homozygous for c.112G>C [p.G38R]. Both individuals showed a reduction of whole blood manganese, though transferrin glycosylation was normal. N-glycome using MALDI-TOF MS identified an increase of the asialo-agalactosylated precursor N-glycan A2G1S1 and a decrease in bisected structures. In addition, analysis of heterozygous CDG-allele carriers identified similar but less severe glycosylation changes. Despite its reliance as a clinical gold standard, analysis of transferrin glycosylation cannot be categorically used to rule out SLC39A8-CDG. These results emphasize that SLC39A8-CDG presents as a spectrum of dysregulated glycosylation, and MS is an important tool for identifying deficiencies not detected by conventional methods.

摘要

先天性糖基化障碍(CDG)是一组不断增加的遗传性代谢疾病,具有多器官表现。SLC39A8-CDG 是一种严重的亚型,由锰转运蛋白 SLC39A8 的双等位基因突变引起,降低了许多酶包括糖基转移酶的这种必需辅因子的水平。目前,N-糖基化紊乱的诊断标准是血清转铁蛋白分析。对两名具有严重神经发育表型的患者进行了外显子组和 Sanger 测序,这些表型提示 CDG。除了使用基质辅助激光解吸电离飞行时间(MALDI-TOF)质谱(MS)进行综合 N-聚糖分析外,还通过高效液相色谱(HPLC)和等电聚焦分析转铁蛋白糖基化。原子吸收光谱用于定量全血锰水平。两名患者均表现出严重的多系统疾病和复杂的神经表型。磁共振成像(MRI)显示类似于 Leigh 的综合征,基底节区双侧 T2 高信号。在患者 1 中,外显子组测序鉴定了先前未描述的 SLC39A8 同源纯合变体 c.608T>C [p.F203S]。患者 2 被发现为 c.112G>C [p.G38R]的纯合子。尽管转铁蛋白糖基化正常,但两个人的全血锰都减少了。使用 MALDI-TOF MS 的 N-聚糖分析鉴定出无唾液酸-半乳糖基化前体 N-聚糖 A2G1S1 的增加和双分叉结构的减少。此外,对杂合 CDG-等位基因携带者的分析鉴定出类似但程度较轻的糖基化变化。尽管它作为临床金标准,但转铁蛋白糖基化分析不能被明确用于排除 SLC39A8-CDG。这些结果强调 SLC39A8-CDG 表现为糖基化失调谱,MS 是识别常规方法无法检测到的缺陷的重要工具。

相似文献

2
Clinical, molecular and glycophenotype insights in SLC39A8-CDG.SLC39A8-CDG 的临床、分子和糖表型见解。
Orphanet J Rare Dis. 2021 Jul 10;16(1):307. doi: 10.1186/s13023-021-01941-y.
8
ALG12-CDG: novel glycophenotype insights endorse the molecular defect.ALG12-CDG:新型聚糖表型见解证实了分子缺陷。
Glycoconj J. 2019 Dec;36(6):461-472. doi: 10.1007/s10719-019-09890-2. Epub 2019 Sep 16.

本文引用的文献

6
Unsuccessful intravenous D-mannose treatment in PMM2-CDG.PMM2-CDG 患者静脉注射 D-甘露糖治疗无效。
Orphanet J Rare Dis. 2019 Oct 22;14(1):231. doi: 10.1186/s13023-019-1213-3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验